Stocks / NASDAQ / Nektar Therapeutics

Nektar Therapeutics

Our Opinion

Nektar Therapeutics is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical analysis and clinical research.

Supporting Evidence:

The company stated in the following report that their drug candidate NKTR-214 is under preclinical phase where it is being studied in research by way of in vitro studies and/or animal studies.

“Research/Preclinical — a drug candidate is being studied in research by way of in vitro studies and/or animal studies.” (Page 9) Read the full document

Company Description

Nektar Therapeutics is a clinical-stage biopharmaceutical company, which engages in developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms. Its products includes of drug candidates of therapeutic areas, including oncology, pain, anti-infectives, anti-viral, and immunology. It provides small molecule drugs, peptides and other potential biologic drug candidates. It’s drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. The company was founded in 1990 and is headquartered in San Francisco, CA. [Source: MarketWatch]

Company Website: